4.5 Article

EUROPEAN CONSENSUS TABLE ON THE USE OF BOTULINUM TOXIN TYPE A IN ADULT SPASTICITY

Journal

JOURNAL OF REHABILITATION MEDICINE
Volume 41, Issue 1, Pages 13-25

Publisher

FOUNDATION REHABILITATION INFORMATION
DOI: 10.2340/16501977-0303

Keywords

botulinum toxin; upper motor neurone syndrome; adult spasticity; acquired brain injury

Funding

  1. Allergan
  2. Ipsen
  3. Merz
  4. Elan
  5. Medtronic
  6. Novartis
  7. Boehringer

Ask authors/readers for more resources

A group of clinicians from across Europe experienced in the use of botulinum toxin type a for the treatment of spasticity following acquired brain injury gathered to develop a consensus statement on best practice in managing adults with spasticity. this consensus table summarizes the current published data, which was collated following extensive literature searches, their assessment for level of evidence and discussion among the whole group. published information is supplemented by expert opinion based on clinical experience from 16 European countries, involving 28 clinicians, who treat an average of approximately 200 patients annually, representing many thousand spasticity treatments with botulinum toxin per year.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available